Vor Bio appoints two industry veterans to its board of directors

CAMBRIDGE, Mass. - Clinical-stage biotechnology company Vor Bio (NASDAQ:VOR) announced Monday the appointment of Alexander (Bo) Cumbo and Michel Detheux, Ph.D., to its Board of Directors, effective July 16, 2025. The company, with a market capitalization of $276 million, has seen its stock surge 139% over the past year, according to InvestingPro data.

Cumbo currently serves as President and Chief Executive Officer of Solid Biosciences and brings over 30 years of commercial and executive leadership experience. He previously served as Executive Vice President and Chief Commercial Officer at Sarepta Therapeutics, where he helped launch multiple rare disease therapies.

Detheux is the President and CEO of iTeos Therapeutics, which he co-founded. Under his leadership, iTeos raised over $1 billion in capital, completed an IPO, and secured a $2 billion partnership with GSK to co-develop the company’s anti-TIGIT antibody.

"Bo and Michel are proven leaders with highly complementary experience across drug development, commercialization, and corporate strategy in cutting-edge therapeutic areas," said Jean-Paul Kress, CEO and Chairman of Vor Bio, according to the company’s press release.

Vor Bio is currently advancing telitacicept, a dual-target fusion protein, through Phase 3 clinical development for autoantibody-driven conditions.

The company, which trades on the Nasdaq, focuses on developing treatments for autoimmune diseases. The appointments come as Vor Bio continues its clinical development programs and potential commercialization efforts.

In other recent news, Vor Bio has been making significant strides with its recent developments. The company announced a major licensing agreement with RemeGen Co., Ltd., granting Vor Bio global rights to develop and commercialize telitacicept outside of China. This deal involves an initial payment of $125 million and could potentially lead to over $4 billion in milestone payments, along with tiered royalties. H.C. Wainwright has upgraded Vor Bio’s stock rating to Buy, citing the licensing agreement as a key factor in strengthening the company’s asset portfolio and finances. Additionally, Vor Bio is advancing telitacicept through Phase 3 clinical trials for generalized myasthenia gravis, with initial data expected in 2027.

In leadership news, Vor Bio appointed Qing Zuraw as Chief Development Officer and Sandy Mahatme as Chief Financial Officer and Chief Business Officer. Zuraw brings extensive experience in clinical development, while Mahatme has a strong background in financial leadership within the biopharmaceutical industry. These appointments come at a pivotal time for Vor Bio as it transitions from early-stage oncology to late-stage autoimmune disease. Stifel maintains a Hold rating on Vor Bio’s stock, noting the strategic repositioning and the potential of telitacicept in ongoing global trials.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.